Eliquis Regulatory Post Marketing Surveillance (rPMS)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Venous Thromboembolism

Treatments: Drug: Apixaban

Study type: Observational

Funder types: Industry

Identifiers

NCT01885585

CV185-222

Details and patient eligibility

About

The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice

Enrollment: 100 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed data release
• Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty

Exclusion criteria

• Being treated for an indication not approved for the use of Eliquis® in Korea
• Is contraindicated for the use of Eliquis® as described in the Korean label

Trial design

100 participants in 1 patient group

Patients with risk of VTE

Description:

Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release

Treatment:

Drug: Apixaban